Literature DB >> 29146710

JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms.

Waihay J Wong1,2, Robert P Hasserjian2,3, Geraldine S Pinkus1,2, Lawrence J Breyfogle4,5, Ann Mullally2,5, Olga Pozdnyakova6,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29146710      PMCID： PMC5792288          DOI： 10.3324/haematol.2017.178988

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.

Authors:  Umberto Gianelli; Anna Bossi; Ivan Cortinovis; Elena Sabattini; Claudio Tripodo; Emanuela Boveri; Alessia Moro; Riccardo Valli; Maurilio Ponzoni; Ada M Florena; Giulio F Orcioni; Stefano Ascani; Emanuela Bonoldi; Alessandra Iurlo; Luigi Gugliotta; Vito Franco
Journal:  Mod Pathol       Date:  2013-11-08       Impact factor: 7.842

2.  Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Authors:  Elisa Rumi; Daniela Pietra; Cristiana Pascutto; Paola Guglielmelli; Alejandra Martínez-Trillos; Ilaria Casetti; Dolors Colomer; Lisa Pieri; Marta Pratcorona; Giada Rotunno; Emanuela Sant'Antonio; Marta Bellini; Chiara Cavalloni; Carmela Mannarelli; Chiara Milanesi; Emanuela Boveri; Virginia Ferretti; Cesare Astori; Vittorio Rosti; Francisco Cervantes; Giovanni Barosi; Alessandro M Vannucchi; Mario Cazzola
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

Review 3.  Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.

Authors:  William Vainchenker; Robert Kralovics
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

Review 4.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

5.  Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.

Authors:  Michael J Kluk; R Coleman Lindsley; Jon C Aster; Neal I Lindeman; David Szeto; Dimity Hall; Frank C Kuo
Journal:  J Mol Diagn       Date:  2016-07       Impact factor: 5.568

6.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Authors:  Pontus Lundberg; Axel Karow; Ronny Nienhold; Renate Looser; Hui Hao-Shen; Ina Nissen; Sabine Girsberger; Thomas Lehmann; Jakob Passweg; Martin Stern; Christian Beisel; Robert Kralovics; Radek C Skoda
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

Review 7.  Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Leukemia       Date:  2013-03-07       Impact factor: 11.528

8.  Effect of mutation order on myeloproliferative neoplasms.

Authors:  Christina A Ortmann; David G Kent; Jyoti Nangalia; Yvonne Silber; David C Wedge; Jacob Grinfeld; E Joanna Baxter; Charles E Massie; Elli Papaemmanuil; Suraj Menon; Anna L Godfrey; Danai Dimitropoulou; Paola Guglielmelli; Beatriz Bellosillo; Carles Besses; Konstanze Döhner; Claire N Harrison; George S Vassiliou; Alessandro Vannucchi; Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

9.  Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Authors:  Paola Guglielmelli; Annalisa Pacilli; Giada Rotunno; Elisa Rumi; Vittorio Rosti; Federica Delaini; Margherita Maffioli; Tiziana Fanelli; Alessandro Pancrazzi; Daniela Pietra; Silvia Salmoiraghi; Carmela Mannarelli; Annalisa Franci; Chiara Paoli; Alessandro Rambaldi; Francesco Passamonti; Giovanni Barosi; Tiziano Barbui; Mario Cazzola; Alessandro M Vannucchi
Journal:  Blood       Date:  2017-03-28       Impact factor: 25.476

10.  Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.

Authors:  D Pietra; E Rumi; V V Ferretti; C A Di Buduo; C Milanesi; C Cavalloni; E Sant'Antonio; V Abbonante; F Moccia; I C Casetti; M Bellini; M C Renna; E Roncoroni; E Fugazza; C Astori; E Boveri; V Rosti; G Barosi; A Balduini; M Cazzola
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528
View more
  7 in total

Review 1.  Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.

Authors:  Zhuang Zuo; Shaoying Li; Jie Xu; M James You; Joseph D Khoury; C Cameron Yin
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

2.  TET2, DNMT3A, IDH1, and JAK2 Mutation in Myeloproliferative Neoplasms in southern Iran.

Authors:  E Abedi; M Ramzi; M Karimi; R Yaghobi; H Mohammadi; E Bayat; M Moghadam; F Farokhian; M Dehghani; H A Golafshan; S Haghpanah
Journal:  Int J Organ Transplant Med       Date:  2021

3.  Oncogenic and tumor suppressor genes expression in myeloproliferative neoplasms: The hidden side of a complex pathology.

Authors:  Elham Abedi; Mehran Karimi; Ramin Yaghobi; Hamid Mohammadi; Sezaneh Haghpanah; Mohamad Moghadam; Elahe Bayat; Alireza Rezvani; Mani Ramzi
Journal:  J Clin Lab Anal       Date:  2022-02-17       Impact factor: 2.352

4.  Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures.

Authors:  Waihay J Wong; Michele Baltay; Annaliese Getz; Kit Fuhrman; Jon C Aster; Robert P Hasserjian; Olga Pozdnyakova
Journal:  PLoS One       Date:  2019-05-09       Impact factor: 3.240

5.  Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms.

Authors:  Milica Vukotić; Sunčica Kapor; Teodora Dragojević; Dragoslava Đikić; Olivera Mitrović Ajtić; Miloš Diklić; Tijana Subotički; Emilija Živković; Bojana Beleslin Čokić; Aleksandar Vojvodić; Juan F Santibáñez; Mirjana Gotić; Vladan P Čokić
Journal:  Exp Mol Med       Date:  2022-03-14       Impact factor: 12.153

6.  The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.

Authors:  Amina Kurtovic-Kozaric; Erna Islamagic; Hana Komic; Nurija Bilalovic; Izet Eminovic; Adnan Burekovic; Amna Uzunovic; Sabira Kurtovic
Journal:  Bosn J Basic Med Sci       Date:  2020-05-01       Impact factor: 3.363

7.  Children and Adolescents with Chronic Myeloproliferative Neoplasms: Still an Unmet Biological and Clinical Need?

Authors:  Tariq I Mughal; Michael W Deininger; Nicole Kucine; Giuseppe Saglio; Richard A Van Etten
Journal:  Hemasphere       Date:  2019-08-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.